KI löst die Probleme der statistischen Programmierung in klinischen Studien: Vcare Medical sucht Finanzierung
Clinical statistics programming is a crucial step before the market launch of drugs. However, the traditional model heavily relies on manual SAS code creation to process the vast amounts of patient data. This process is time - consuming and error - prone. OpenGraphs (also known as 「Weikeli Medicine」), which focuses on improving clinical trial data statistics with AI, tries to change this situation. Currently, the company is seeking a new round of financing.
OpenGraphs was founded in December 2025 and focuses on providing AI - driven solutions for the entire clinical trial process for the global pharmaceutical industry. The starting point of the company is one of the most labor - intensive and repetitive steps in clinical trials - programming for clinical data statistics and analysis. The founder and CEO, Wei Xingchen, has a master's degree in biostatistics and epidemiology from the University of Southern California and understands very well the weaknesses in the data flow of clinical trials. The CTO, Wang Xinrui, is a doctoral candidate in the field of large models at the University of Tokyo and has the ability to implement leading AI technologies in practice.
Main obstacle: The efficiency limit of statistics programming hinders the market launch of new drugs
In clinical drug trials, statistics programmers must convert the huge amounts of original case data into analysis results that can be reviewed by drug regulatory authorities using tools such as SAS and R. This process not only requires writing thousands of lines of code but also repeated validation and modification, which can take months. With the increasing complexity of clinical trial designs, the manual programming model has become one of the main limiting factors that hinder the efficiency of trials and increase research and development costs. The global AI market in the healthcare sector is growing rapidly. Using AI to support clinical data analysis is regarded as a reliable way to improve efficiency and reduce costs.
Solution: Automatic code generation with large models
OpenGraphs' first product - the AI data analysis tool - targets exactly this problem. The tool is based on large language model technology and has been fine - tuned with professional corpora in the field of clinical statistics. It can understand the statistical analysis plan (SAP) and automatically generate statistical analysis code that meets regulatory requirements.
「Our goal is not to replace statisticians, but to free programmers from the tedious, repetitive coding,」 said founder Wei Xingchen. 「Ideally, the AI can handle 95% of the basic coding work. Humans only need to review and fine - tune. This will significantly shorten the data analysis time and reduce the risk of human errors.」
In addition, the company has a clear five - year product plan: Starting with the current data analysis tool, products such as AI Medical Writer (automatic generation of clinical research reports), AI regulatory registration tool and AI drug warning tool will be launched in the future. Finally, an AI - supported platform covering the entire clinical trial process is to be created.
Team background: In - depth integration of industry experience and AI technology
The team composition is one of the core advantages of OpenGraphs.
· Chief medical advisor Wei Gang: He has over 35 years of experience in clinical and pharmaceutical research and was once a senior medical director at Fosun Pharma's global research and development center. He has rich practical experience in the clinical development and market launch of innovative drugs.
· Chief AI advisor Yutaka Matsuo: A professor at the University of Tokyo, the chairman of the Japanese AI Strategy Conference and a non - executive director of the SoftBank Group. He is one of the most influential academic experts in the Japanese AI field.
· Core team: It consists of professionals from various fields such as biostatistics, clinical operations and large - model algorithms and has the ability to deeply integrate technology and industry requirements.
·
Business model and market potential
The company has clear target customers, mainly large and medium - sized pharmaceutical companies at home and abroad as well as CROs (contract research organizations). The business model is based on SaaS subscriptions and project - based services to offer customers standardized tools and customized solutions.
The world's top 20 pharmaceutical companies spend more than $5 billion annually on the operation of clinical trials. A 1% increase in the penetration rate of AI - supported tools already means a market worth billions of US dollars.
Current status and planning
The company has completed the product concept review and is currently in contact with interested pharmaceutical companies for POC (Proof of Concept) cooperation. The financing in this round will be mainly used for the following purposes:
Product iteration: Complete product packaging of the AI data analysis tool.
Market testing: Promote pilot cooperation with 2 - 3 leading pharmaceutical companies or CROs in the country.
Team strengthening: Recruit core personnel such as clinical data experts and algorithm engineers.
OpenGraphs hopes to start from the least efficient step in clinical trials and bring about a practical change in this strict and traditional industry with AI.